首頁 > 市場調查報告書 > 製藥

全球特應性皮炎藥物市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1342844

全球特應性皮炎藥物市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Atopic Dermatitis Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球特應性皮炎藥物市場需求預計將從 2022 年的 96.3 億美元增至 2030 年的近 348.2 億美元，2023-2030 年研究期間年複合成長率為 17.43%。

特應性皮炎 (AD) 是最常見的濕疹類型，影響著世界上很大一部分人口。這種情況可能發生在任何年齡段的人，但在新生兒和兒童中最常見，並且隨著年齡的成長而好轉。

市場動態：

更多生物製劑和小分子藥物的推出、高價藥物替代一線和二線學名藥、診斷方法的改進以及 AD 發病率的上升等主要因素預計將促進特應性皮炎藥物市場的成長。此外，人們對該疾病治療方法的認知不斷提高，幫助該市場在過去幾年中獲得了吸引力。然而，高昂的治療成本是市場向上攀升的關鍵障礙之一。無論如何，政府為提供更好、更實惠的治療和有利的報銷政策而採取的舉措可能會為市場提供新的機會。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球特應性皮炎藥物市場的各個細分市場進行了包容性評估。特應性皮炎藥物行業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲特應性皮炎藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。特應性皮炎藥物市場的主要參與者包括輝瑞公司、艾伯維公司、賽諾菲公司、Galderma Laboratories, LP、禮來公司（Dermira）、再生元製藥公司、LEO Pharma Inc.、大塚製藥有限公司、諾華公司、Incyte 公司。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概述、歷史和預測銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：特應性皮炎藥品公司的競爭格局

特應性皮炎藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市場佔有率分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Galderma Laboratories LP

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company (Dermira)

公司簡介
公司收入
產品
最近的發展

Regeneron Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

LEO Pharma Inc.

公司簡介
公司收入
產品
最近的發展

Otsuka Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Incyte Corporation

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR11219522

The global demand for Atopic Dermatitis Drugs Market is presumed to reach the market size of nearly USD 34.82 BN by 2030 from USD 9.63 BN in 2022 with a CAGR of 17.43% under the study period 2023 - 2030.

Atopic dermatitis (AD) refers to the most common type of eczema, affecting a large percentage of the world's population. The condition can strike an individual at any age but is most common in newborns and children and becomes better as people get older.

MARKET DYNAMICS:

Major factors such as the launch of more biologics & small molecules, high-priced drugs substituting generic first-line and second-line therapeutics, improved diagnostics and growing incidence of AD is estimated to augment the atopic dermatitis drugs market growth. Furthermore, a rise in awareness regarding the availability of treatments for the disease has helped the market gain traction over the past few years. However, the high cost of therapeutics is one of the key roadblocks in the market's upward climb. Regardless, initiatives undertaken by governments to provide better and more affordable treatment and favourable reimbursement policies are likely to provide new opportunities in the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of atopic dermatitis drugs. The growth and trends of atopic dermatitis drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the atopic dermatitis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Pde4 Inhibitors
Biologics
Others

By Route Of Administration

Topical
Injectable
Oral

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Atopic Dermatitis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the atopic dermatitis drugs market include Pfizer Inc., AbbVie Inc., Sanofi, Galderma Laboratories, L.P., Eli Lilly and Company (Dermira), Regeneron Pharmaceuticals Inc., LEO Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, Incyte Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ATOPIC DERMATITIS DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route Of Administration
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Corticosteroids Historic and Forecast Sales by Regions
6.5 Calcineurin Inhibitors Historic and Forecast Sales by Regions
6.6 PDE4 Inhibitors Historic and Forecast Sales by Regions
6.7 Biologics Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route Of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route Of Administration
7.4 Topical Historic and Forecast Sales by Regions
7.5 Injectable Historic and Forecast Sales by Regions
7.6 Oral Historic and Forecast Sales by Regions

8 . GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ATOPIC DERMATITIS DRUGS COMPANIES

9.1. Atopic Dermatitis Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF ATOPIC DERMATITIS DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AbbVie Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Sanofi
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Galderma Laboratories L.P.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Eli Lilly and Company (Dermira)
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Regeneron Pharmaceuticals Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. LEO Pharma Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Otsuka Pharmaceutical Co. Ltd.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Novartis AG
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Incyte Corporation
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments